Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Helle Lynggaard1, Oliver N Keene2, Tobias Mütze3

  • 1Novo Nordisk A/S, Bagsvaerd, Denmark.

Pharmaceutical statistics
|August 8, 2024
PubMed
概括
此摘要是机器生成的。

本文讨论了将估计和框架应用于非劣等性试验的挑战. 它为这些试验定义估值提供了指导,确保了 robust 临床试验设计和解释.

科学领域:

  • 临床试验方法论 临床试验方法论
  • 生物统计学 生物统计学
  • 药学研究 药学研究
关键词:
ICH E9 ((R1)) 的意思是有关临床兴趣的问题.估计和框架 估计和框架没有劣势的非劣势.监管指南 监管指南 监管指南优越性的优越性

相关实验视频

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Covariate Adjustment for the Win Odds: Application to Cardiovascular Outcomes Trials.

Statistics in medicine·2026
Same author

Inverse Probability Weighting for Recurrent Event Models.

Statistics in medicine·2026
Same author

Using Off-Treatment Sequential Multiple Imputation for Binary Outcomes to Address Intercurrent Events Handled by a Treatment Policy Strategy.

Pharmaceutical statistics·2026
Same author

Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 Trial.

Pharmaceutical statistics·2025
Same author

Applying the estimand framework to clinical pharmacology trials with a case study in bioequivalence.

British journal of clinical pharmacology·2024
Same author

Stakeholders' Perspectives on Current Issues in Data Monitoring Committees.

Biometrical journal. Biometrische Zeitschrift·2024
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
查看所有相关文章